Context Temozolomide (TMZ) is endorsed as the treatment of choice in aggressive or
malignant pituitary adenomas. Objective Herein we describe a case of an aggressive …

Prolactinomas are common tumors of the anterior pituitary gland. While conventional
therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are …

Abstract According to the World Health Organization classification of pituitary tumors, only
tumors with systemic metastasis must be considered as carcinomas. Invasive tumors with …

Prolactinomas are the most common hormone-secreting pituitary adenomas, comprising
40% of all pituitary tumors. Prolactinomas present a unique challenge for clinicians, as these …

A small subset of lactotroph adenomas is resistant to dopamine agonists (DA) and can also
demonstrate aggressive or even malignant behavior. The implicated mechanisms are not …

Prolactin-secreting tumors (prolactinomas) represent the most common pituitary tumor type,
accounting for 47–66% of functional pituitary tumors. Prolactinomas are usually benign and …

Methods: This GL has been developed following the methods described in the Manual of the
Italian National Guideline System. For each question, the panel appointed by Associazione …

Consensus guidelines recommend dopamine agonists (DAs) as the mainstay treatment for
prolactinomas. In most patients, DAs achieve tumor shrinkage and normoprolactinemia at …

The authors present an update on the various treatment modalities and discuss
management strategies for prolactinomas. Prolactinomas are the most common type of …

Introduction: Prolactinomas represent the most common pituitary adenomas encountered in
the clinic. While a majority of these tumors will be successfully treated by dopamine agonist …